SCAL Stock Overview

A technology development company, focuses on the collection and cryogenic preservation of stem cells. More details

SCAL fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

Does not have a meaningful market cap ($9M)

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

Stem Cell Authority, Ltd. Competitors

Kindly MD

NasdaqCM:KDLY

US$9.7m

Precipio

NasdaqCM:PRPO

US$9.2m

Ontrak

NasdaqCM:OTRK

US$7.8m

Syra Health

NasdaqCM:SYRA

US$8.7m

Price History & Performance

Summary of share price highs, lows and changes for Stem Cell Authority
Historical stock prices
Current Share Price	US$0.0045
52 Week High	US$0.057
52 Week Low	US$0.0008
Beta	0
1 Month Change	-69.18%
3 Month Change	2.27%
1 Year Change	462.50%
3 Year Change	-57.14%
5 Year Change	449,900.00%
Change since IPO	-91.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	SCAL	US Healthcare	US Market
7D	0%	1.3%	-2.1%
1Y	462.5%	-7.4%	21.3%

Return vs Industry: SCAL exceeded the US Healthcare industry which returned -7% over the past year.

Return vs Market: SCAL exceeded the US Market which returned 23.2% over the past year.

Price Volatility

Is SCAL's price volatile compared to industry and market?
SCAL volatility
SCAL Average Weekly Movement	n/a
Healthcare Industry Average Movement	7.8%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.8%
10% least volatile stocks in US Market	3.2%

Stable Share Price: SCAL's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine SCAL's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Carlzo Cardwell	www.stemcellauthority.com

Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells. It specializes in the collection and cryogenic preservation of the hematopoietic stem cells from the umbilical cord blood; and the Miracle Mesenchymal stem cells from the Wharton’s jelly inside the umbilical cord of a newborn child. The company’s technology enables birthing professionals with a stem cell preservation program to serve their maternity patients in the United States.

Stem Cell Authority, Ltd. Fundamentals Summary

How do Stem Cell Authority's earnings and revenue compare to its market cap?
SCAL fundamental statistics
Market cap	US$8.91m
Earnings (TTM)	US$1.83m
Revenue (TTM)	US$3.33m

0.0x

P/E Ratio

0.0x

P/S Ratio

Is SCAL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SCAL income statement (TTM)
Revenue	US$3.33m
Cost of Revenue	US$1.06m
Gross Profit	US$2.27m
Other Expenses	US$436.45k
Earnings	US$1.83m

Last Reported Earnings

Aug 31, 2009

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did SCAL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/10 15:48
End of Day Share Price	2024/12/31 00:00
Earnings	2009/08/31
Annual Earnings	2009/08/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Stem Cell Authority, Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution